Drug Trial Radar · NCT04897412
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
Last checked: Nov 19, 2026Latest source record: Apr 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Feb 14, 2022
Primary completion
Feb 22, 2023
Study completion Mar 22, 2023
Sponsor
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.
Conditions
- Subcutaneous Fat
Interventions
CBL-514 InjectionDrug
Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
PlaceboOther
Sodium Chloride (0.9% NaCl) placebo for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who lose at least 150 mL of subcutaneous fat compared with placeboTime frame: From Visit 2 (Baseline) up to 8 weeks after last treatment
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Investigational site 1
Chicago, Illinois
Investigational site 2
Omaha, Nebraska
Investigational site 3
Nashville, Tennessee
Investigational site 4
Austin, Texas
Investigational site 5
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.